文献速递心境障碍焦虑、强迫与应激相关障碍

SARS-CoV-2感染后成人发生心境障碍或焦虑障碍诊断或治疗的风险,2020-2022

Risk for diagnosis or treatment of mood or anxiety disorders in adults after SARS-CoV-2 infection, 2020-2022.
PubMed 文献 · Mol Psychiatry · 2024-01-18

该回顾性队列研究基于全国电子健康记录数据库,纳入822,756例COVID-19患者与2,034,353例其他呼吸道感染患者,采用倾向评分匹配和Kaplan-Meier生存分析比较感染后14天至3个月内新发抑郁或焦虑障碍诊断及抗抑郁/抗焦虑药物处方风险。结果显示,疫情初期(2020年1-3月)COVID-19患者风险显著升高(HR 1.65),随后至2022年1-4月风险增幅减弱(HR 1.08-1.12);≥65岁患者绝对风险最高(6.8%),女性风险高于男性(HR 1.35)。

要点

  • 疫情初期COVID-19后3个月内抑郁或焦虑障碍诊断风险显著升高(HR 1.65)。
  • 随时间推移风险增幅减弱,2022年1-4月HR降至1.08。
  • ≥65岁患者绝对风险最高(6.8%),女性风险高于男性(HR 1.35)。

核心结论

  • SARS-CoV-2感染后3个月内抑郁或焦虑障碍诊断及治疗风险升高,疫情初期最显著,随时间推移减弱。

研究设计与样本

  • 回顾性队列研究,使用全国电子健康记录数据库,纳入822,756例COVID-19患者和2,034,353例其他呼吸道感染患者,按3个月时间段分析2020年1月至2022年4月。

主要发现

  • 疫情初期(2020年1-3月)COVID-19患者抑郁或焦虑障碍诊断风险显著升高(HR 1.65 [95% CI, 1.30-2.08])。
  • 抗抑郁药和抗焦虑药处方呈现相似时间模式,以骨折患者为对照、分别分析焦虑和抑郁障碍、检测复发性抑郁障碍及延长至6个月时结果一致。
  • ≥65岁COVID-19患者疫情初期绝对风险最高(6.8%),整个研究期间持续较高(HR 1.20 [95% CI, 1.13-1.27])。
  • 女性COVID-19患者风险高于男性(HR 1.35 [95% CI, 1.30-1.40])。

临床怎么用

  • 对SARS-CoV-2感染后患者,尤其在疫情初期感染、高龄(≥65岁)及女性群体,应关注抑郁和焦虑障碍的筛查与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 is associated with increased risks for mood or anxiety disorders, but it remains uncertain how the association evolves over time or which patient groups are most affected. We conducted a retrospective cohort study using a nationwide database of electronic health records to determine the risk of depressive or anxiety disorder diagnoses after SARS-CoV-2 infection by 3-month blocks from January 2020 to April 2022. The study population comprised 822,756 patients (51.8% female; mean age 42.8 years) with COVID-19 and 2,034,353 patients with other respiratory tract infections (RTIs) (53.5% female, mean age 30.6 years). First time diagnoses of depressive or anxiety disorders 14 days to 3 months after infection, as well as new or new plus recurrent prescriptions of antidepressants or anxiolytics, were compared between propensity score matched cohorts using Kaplan-Meier survival analysis, including hazard ratio (HR) and 95% confidence interval (CI). Risk of a new diagnosis or prescription was also stratified by age, sex, and race to better characterize which groups were most affected. In the first three months of the pandemic, patients infected with SARS-CoV-2 had significantly increased risk of depression or anxiety disorder diagnosis (HR 1.65 [95% CI, 1.30-2.08]). October 2021 to January 2022 (HR, 1.12 [95% CI, 1.06-1.18]) and January to April 2022 (HR, 1.08 [95% CI, 1.01-1.14]). Similar temporal patterns were observed for antidepressant and anxiolytic prescriptions, when the control group was patients with bone fracture, when anxiety and depressive disorders were considered separately, when recurrent depressive disorder was tested, and when the test period was extended to 6 months. COVID-19 patients ≥65 years old demonstrated greatest absolute risk at the start of the pandemic (6.8%), which remained consistently higher throughout the study period (HR, 1.20 [95% CI, 1.13-1.27]), and overall, women with COVID-19 had greater risk than men (HR 1.35 [95% CI 1.30-1.40]).

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wang CX, Kohli R, Olaker VR, et al. Risk for diagnosis or treatment of mood or anxiety disorders in adults after SARS-CoV-2 infection, 2020-2022. Mol Psychiatry. 2024. PMID: 38238547. doi:10.1038/s41380-024-02414-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。